Cargando…
Preclinical evaluation of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B
Safe and effective vaccines are needed to end the COVID-19 pandemic. Here, we report the preclinical development of a lipid nanoparticle–formulated SARS-CoV-2 mRNA vaccine, PTX-COVID19-B. PTX-COVID19-B was chosen among three candidates after the initial mouse vaccination results showed that it elici...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for the Advancement of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8769538/ https://www.ncbi.nlm.nih.gov/pubmed/35044832 http://dx.doi.org/10.1126/sciadv.abj9815 |
_version_ | 1784635166914772992 |
---|---|
author | Liu, Jun Budylowski, Patrick Samson, Reuben Griffin, Bryan D. Babuadze, Giorgi Rathod, Bhavisha Colwill, Karen Abioye, Jumai A. Schwartz, Jordan A. Law, Ryan Yip, Lily Ahn, Sang Kyun Chau, Serena Naghibosadat, Maedeh Arita, Yuko Hu, Queenie Yue, Feng Yun Banerjee, Arinjay Hardy, W. Rod Mossman, Karen Mubareka, Samira Kozak, Robert A. Pollanen, Michael S. Martin Orozco, Natalia Gingras, Anne-Claude Marcusson, Eric G. Ostrowski, Mario A. |
author_facet | Liu, Jun Budylowski, Patrick Samson, Reuben Griffin, Bryan D. Babuadze, Giorgi Rathod, Bhavisha Colwill, Karen Abioye, Jumai A. Schwartz, Jordan A. Law, Ryan Yip, Lily Ahn, Sang Kyun Chau, Serena Naghibosadat, Maedeh Arita, Yuko Hu, Queenie Yue, Feng Yun Banerjee, Arinjay Hardy, W. Rod Mossman, Karen Mubareka, Samira Kozak, Robert A. Pollanen, Michael S. Martin Orozco, Natalia Gingras, Anne-Claude Marcusson, Eric G. Ostrowski, Mario A. |
author_sort | Liu, Jun |
collection | PubMed |
description | Safe and effective vaccines are needed to end the COVID-19 pandemic. Here, we report the preclinical development of a lipid nanoparticle–formulated SARS-CoV-2 mRNA vaccine, PTX-COVID19-B. PTX-COVID19-B was chosen among three candidates after the initial mouse vaccination results showed that it elicited the strongest neutralizing antibody response against SARS-CoV-2. Further tests in mice and hamsters indicated that PTX-COVID19-B induced robust humoral and cellular immune responses and completely protected the vaccinated animals from SARS-CoV-2 infection in the lung. Studies in hamsters also showed that PTX-COVID19-B protected the upper respiratory tract from SARS-CoV-2 infection. Mouse immune sera elicited by PTX-COVID19-B vaccination were able to neutralize SARS-CoV-2 variants of concern, including the Alpha, Beta, Gamma, and Delta lineages. No adverse effects were induced by PTX-COVID19-B in either mice or hamsters. Based on these results, PTX-COVID19-B was authorized by Health Canada to enter clinical trials in December 2020 with a phase 2 clinical trial ongoing. |
format | Online Article Text |
id | pubmed-8769538 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | American Association for the Advancement of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-87695382022-02-01 Preclinical evaluation of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B Liu, Jun Budylowski, Patrick Samson, Reuben Griffin, Bryan D. Babuadze, Giorgi Rathod, Bhavisha Colwill, Karen Abioye, Jumai A. Schwartz, Jordan A. Law, Ryan Yip, Lily Ahn, Sang Kyun Chau, Serena Naghibosadat, Maedeh Arita, Yuko Hu, Queenie Yue, Feng Yun Banerjee, Arinjay Hardy, W. Rod Mossman, Karen Mubareka, Samira Kozak, Robert A. Pollanen, Michael S. Martin Orozco, Natalia Gingras, Anne-Claude Marcusson, Eric G. Ostrowski, Mario A. Sci Adv Biomedicine and Life Sciences Safe and effective vaccines are needed to end the COVID-19 pandemic. Here, we report the preclinical development of a lipid nanoparticle–formulated SARS-CoV-2 mRNA vaccine, PTX-COVID19-B. PTX-COVID19-B was chosen among three candidates after the initial mouse vaccination results showed that it elicited the strongest neutralizing antibody response against SARS-CoV-2. Further tests in mice and hamsters indicated that PTX-COVID19-B induced robust humoral and cellular immune responses and completely protected the vaccinated animals from SARS-CoV-2 infection in the lung. Studies in hamsters also showed that PTX-COVID19-B protected the upper respiratory tract from SARS-CoV-2 infection. Mouse immune sera elicited by PTX-COVID19-B vaccination were able to neutralize SARS-CoV-2 variants of concern, including the Alpha, Beta, Gamma, and Delta lineages. No adverse effects were induced by PTX-COVID19-B in either mice or hamsters. Based on these results, PTX-COVID19-B was authorized by Health Canada to enter clinical trials in December 2020 with a phase 2 clinical trial ongoing. American Association for the Advancement of Science 2022-01-19 /pmc/articles/PMC8769538/ /pubmed/35044832 http://dx.doi.org/10.1126/sciadv.abj9815 Text en Copyright © 2022 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution License 4.0 (CC BY). https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution license (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Biomedicine and Life Sciences Liu, Jun Budylowski, Patrick Samson, Reuben Griffin, Bryan D. Babuadze, Giorgi Rathod, Bhavisha Colwill, Karen Abioye, Jumai A. Schwartz, Jordan A. Law, Ryan Yip, Lily Ahn, Sang Kyun Chau, Serena Naghibosadat, Maedeh Arita, Yuko Hu, Queenie Yue, Feng Yun Banerjee, Arinjay Hardy, W. Rod Mossman, Karen Mubareka, Samira Kozak, Robert A. Pollanen, Michael S. Martin Orozco, Natalia Gingras, Anne-Claude Marcusson, Eric G. Ostrowski, Mario A. Preclinical evaluation of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B |
title | Preclinical evaluation of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B |
title_full | Preclinical evaluation of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B |
title_fullStr | Preclinical evaluation of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B |
title_full_unstemmed | Preclinical evaluation of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B |
title_short | Preclinical evaluation of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B |
title_sort | preclinical evaluation of a sars-cov-2 mrna vaccine ptx-covid19-b |
topic | Biomedicine and Life Sciences |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8769538/ https://www.ncbi.nlm.nih.gov/pubmed/35044832 http://dx.doi.org/10.1126/sciadv.abj9815 |
work_keys_str_mv | AT liujun preclinicalevaluationofasarscov2mrnavaccineptxcovid19b AT budylowskipatrick preclinicalevaluationofasarscov2mrnavaccineptxcovid19b AT samsonreuben preclinicalevaluationofasarscov2mrnavaccineptxcovid19b AT griffinbryand preclinicalevaluationofasarscov2mrnavaccineptxcovid19b AT babuadzegiorgi preclinicalevaluationofasarscov2mrnavaccineptxcovid19b AT rathodbhavisha preclinicalevaluationofasarscov2mrnavaccineptxcovid19b AT colwillkaren preclinicalevaluationofasarscov2mrnavaccineptxcovid19b AT abioyejumaia preclinicalevaluationofasarscov2mrnavaccineptxcovid19b AT schwartzjordana preclinicalevaluationofasarscov2mrnavaccineptxcovid19b AT lawryan preclinicalevaluationofasarscov2mrnavaccineptxcovid19b AT yiplily preclinicalevaluationofasarscov2mrnavaccineptxcovid19b AT ahnsangkyun preclinicalevaluationofasarscov2mrnavaccineptxcovid19b AT chauserena preclinicalevaluationofasarscov2mrnavaccineptxcovid19b AT naghibosadatmaedeh preclinicalevaluationofasarscov2mrnavaccineptxcovid19b AT aritayuko preclinicalevaluationofasarscov2mrnavaccineptxcovid19b AT huqueenie preclinicalevaluationofasarscov2mrnavaccineptxcovid19b AT yuefengyun preclinicalevaluationofasarscov2mrnavaccineptxcovid19b AT banerjeearinjay preclinicalevaluationofasarscov2mrnavaccineptxcovid19b AT hardywrod preclinicalevaluationofasarscov2mrnavaccineptxcovid19b AT mossmankaren preclinicalevaluationofasarscov2mrnavaccineptxcovid19b AT mubarekasamira preclinicalevaluationofasarscov2mrnavaccineptxcovid19b AT kozakroberta preclinicalevaluationofasarscov2mrnavaccineptxcovid19b AT pollanenmichaels preclinicalevaluationofasarscov2mrnavaccineptxcovid19b AT martinorozconatalia preclinicalevaluationofasarscov2mrnavaccineptxcovid19b AT gingrasanneclaude preclinicalevaluationofasarscov2mrnavaccineptxcovid19b AT marcussonericg preclinicalevaluationofasarscov2mrnavaccineptxcovid19b AT ostrowskimarioa preclinicalevaluationofasarscov2mrnavaccineptxcovid19b |